RESUMO
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide, ranging from steatosis to non-alcoholic steatohepatitis (NASH). Recently, cerium oxide nanoparticles (CeO2NPs) have emerged as a new antioxidant agent with hepatoprotective properties in experimental liver disease. The aim of the current investigation was to elucidate whether CeO2NPs display beneficial effects in an experimental model of NAFLD.Therefore, fifteen Wistar rats were subjected to a methionine and choline deficient diet (MCDD) for 6 weeks and intravenously treated with CeO2NP or vehicle during the weeks three and four of the diet. The effect of CeO2NPs on serum biochemistry, hepatic steatosis, inflammation, fatty acid content and expression of reactive oxygen species (ROS) and lipid metabolism related genes was assessed. MCDD fed rats showed increased inflammation, enhanced hepatic lipid accumulation of both saturated and unsaturated fatty acids (FAs) and overexpression of genes related to fatty liver and ROS metabolism. Treatment with CeO2NPs was able to reduce the size and content of hepatocyte lipid droplets, the hepatic concentration of triglyceride- and cholesterol ester-derived FAs and the expression of several genes involved in cytokine, adipokine and chemokine signaling pathways. These findings suggest that CeO2NPs could be of beneficial value in NAFLD.
Assuntos
Cério/uso terapêutico , Nanopartículas/uso terapêutico , Hepatopatia Gordurosa não Alcoólica/tratamento farmacológico , Adipocinas/metabolismo , Animais , Peso Corporal/efeitos dos fármacos , Colesterol/metabolismo , Colina , Dieta , Ácidos Graxos/metabolismo , Regulação da Expressão Gênica/efeitos dos fármacos , Inflamação/patologia , Metabolismo dos Lipídeos , Peroxidação de Lipídeos/efeitos dos fármacos , Fígado/efeitos dos fármacos , Fígado/patologia , Masculino , Malondialdeído/metabolismo , Metionina/deficiência , Nanopartículas/ultraestrutura , Hepatopatia Gordurosa não Alcoólica/sangue , Hepatopatia Gordurosa não Alcoólica/genética , Tamanho do Órgão/efeitos dos fármacos , Estresse Oxidativo/efeitos dos fármacos , Ratos Wistar , Transdução de Sinais , Triglicerídeos/metabolismoRESUMO
BACKGROUND: Because of its potential value in several pathologies, clinical interest in 25-hydroxy Vitamin D (25OH-D) is increasing. However, the standardisation of assays remains a significant problem. Our aim was to evaluate the performance of the novel Lumipulse G 25-OH Vitamin D assay (Fujirebio), comparing results with the Liaison (Diasorin) method. METHODS: Analytical verification of the Lumipulse G 25-OH Vitamin D assay was performed. Both methods were compared using sera from 226 patients, including 111 patients with chronic renal failure (39 on haemodialysis) and 115 patients without renal failure. In addition, clinical concordance between assays was assessed. RESULTS: For Lumipulse G 25-OH Vitamin D assay, the limit of detection was 0.3 ng/mL, and the limit of quantification was 2.5 ng/mL with a 9.7% of coefficient of variation. Intra-and inter-assay coefficients of variation were <2.3 and <1.8% (25.4-50.0 ng/mL), respectively. Dilution linearity was in the range of 4.5-144.5 ng/mL. Method comparison resulted in a mean difference of -6.5% (95% CI from -8.8 to -4.1) for all samples between Liaison and Lumipulse G. Clinical concordance assessed by Kappa Index was 0.66. CONCLUSIONS: Lumipulse G 25-OH Vitamin D showed a good clinical concordance with the Liaison assay, although overall results measured in Lumipulse were higher by an average of 6.5%.
Assuntos
Imunoensaio/métodos , Imunoensaio/normas , Medições Luminescentes/métodos , Medições Luminescentes/normas , Vitamina D/análogos & derivados , Adolescente , Adulto , Idoso , Automação Laboratorial , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Reprodutibilidade dos Testes , Vitamina D/sangue , Adulto JovemRESUMO
No disponible
